Application of diagnostic and treatment criteria for common variable immunodeficiency disorder

Expert Review of Clinical Immunology

Volumn 12, Issue 3, 2016, Pages 257-266

  Ameratunga, Rohan ^a   Storey, Peter ^a   Barker, Russell ^a   Jordan, Anthony ^a   Koopmans, Wikke ^a   Woon, See Tarn ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Common Variable Immunodeficiency; diagnostic criteria; HGUS

Indexed keywords

DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G3; PNEUMOCOCCUS VACCINE; TNFRSF13B PROTEIN, HUMAN; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ABNORMAL LABORATORY RESULT; ADULT; ANTIBODY RESPONSE; ASSESSMENT OF HUMANS; BRONCHIECTASIS; CASE REPORT; CLINICAL FEATURE; COMMON VARIABLE IMMUNODEFICIENCY; COUGHING; ESID DIAGNOSTIC CRITERIA; FEMALE; HETEROZYGOTE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; MALE; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA; ASYMPTOMATIC DISEASE; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; NEW ZEALAND; PEDIGREE;

ADULT; ASYMPTOMATIC DISEASES; BRONCHIECTASIS; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; NEW ZEALAND; PEDIGREE; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN;

EID: 84959477949     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2016.1126509     Document Type: Review

References (51)

1. Gathmann B, Mahlaoui N, Gerard L, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134 (1):116-126.
2. Al-Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2011;2:54.
3. Al-Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2014;5:162.
4. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999;93(3):190-197.
5. Ameratunga R, Woon ST, Gillis D, et al. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol. 2013;174(2):203-211.
6. Agarwal S, Cunningham-Rundles C. Treatment of hypogammaglobulinemia in adults: a scoring system to guide decisions on immunoglobulin replacement. J Allergy Clin Immunol. 2013;131(6):1699-1701.
7. Ameratunga R, Brewerton M, Slade C, et al. Comparison of diagnostic criteria for Common Variable Immunodeficiency Disorder. Front Immunol. 2014;5:414.
8. Abbott JK, Gelfand EW. Common variable immunodeficiency: diagnosis, management, and treatment. Immunol Allergy Clin North Am. 2015;35(4):637-658. doi:10.1016/j. iac.2015.07.009
9. Oksenhendler E, Gerard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46(10):1547-1554.
10. Agarwal S, Cunningham-Rundles C. Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol. 2007;99(3):281-283.
11. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol. 2009;145(6):709-727.
12. Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev. 2006;5(2):156-159.
13. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34-48.
14. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277-286.
15. Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111(1):77-85.
16. Koopmans W, Woon ST, Zeng IS, et al. Variability of memory B cell markers in a cohort of Common Variable Immune Deficiency patients over six months. Scand J Immunol. 2013;33(1):68-73.
17. Olinder-Nielsen AM, Granert C, Forsberg P, et al. Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up. Scand J Infect Dis. 2007;39(1):44-50.
18. Abrahamian F, Agrawal S, Gupta S. Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy. Clin Exp Immunol. 2010;159 (3):344-350.
19. Musher DM, Manof SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010;201(4):516-524.
20. Koopmans W, Woon ST, Brooks AE, et al. Clinical variability of family members with the C104R mutation in transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). J Clin Immunol. 2013;33(1):68-73.
21. Tiller TL Jr, Buckley RH. Transient hypogammaglobulinemia of infancy: review of the literature, clinical and immunologic features of 11 new cases, and long-term follow-up. J Pediatr. 1978;92(3):347-353.
22. Pan-Hammarstrom Q, Salzer U, Du L, et al. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet. 2007;39(4):429-430.
23. Salzer U, Bacchelli C, Buckridge S, et al. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood. 2009;113(9):1967-1976.
24. Popa V. Lymphocytic interstitial pneumonia of common variable immunodeficiency. Ann Allergy. 1988;60(3):203-206.
25. Ameratunga R, Becroft DM, Hunter W. The simultaneous presentation of sarcoidosis and common variable immune deficiency. Pathology. 2000;32(4):280-282.
26. Fasano MB, Sullivan KE, Sarpong SB, et al. Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Medicine (Baltimore). 1996;75(5):251-261.
27. Fuss IJ, Friend J, Yang Z, et al. Nodular regenerative hyperplasia in common variable immunodeficiency. J Clin Immunol. 2013;33(4):748-758.
28. Malamut G, Ziol M, Suarez F, et al. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol. 2008;48(1):74-82.
29. Luzi G, Zullo A, Iebba F, et al. Duodenal pathology and clinical-immunological implications in common variable immunodeficiency patients. Am J Gastroenterol. 2003;98 (1):118-121.
30. Malamut G, Verkarre V, Suarez F, et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenterol. 2010;105(10):2262-2275.
31. Agarwal S, Smereka P, Harpaz N, et al. Characterization of immunologic defects in patients with common variable immunodeficiency (CVID) with intestinal disease. Inflamm Bowel Dis. 2011;17(1):251-259.
32. Empson M, Sinclair J, O'Donnell J, et al. The assessment and management of primary antibody deficiency. N Z Med J. 2004;117(1195):U914.
33. Grabenstein JD, Manoff SB. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults. Vaccine. 2012;30(30):4435-4444.
34. Seppänen M, Aghamohammadi A, Rezaei N. Is there a need to redefine the diagnostic criteria for common variable immunodeficiency? Expert Rev Clin Immunol. 2014;10(1):1-5. doi:10.1586/1744666X.2014.870478. Epub 2013 Dec 10.
35. Yong PF, Thaventhiran JE, Grimbacher B. 'A rose is a rose is a rose,' but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011? Adv Immunol. 2011;111:47-107.
36. Ameratunga R, Woon ST, Gillis D, et al. New diagnostic criteria for CVID. Expert Rev Clin Immunol. 2014;10 (2):183-186.
37. Ameratunga R, Lindsay K, Woon S-T, et al. New diagnostic criteria could distinguish common variable immunodeficiency disorder from anticonvulsant-induced hypogammaglobulinemia. Clin Exp Neuroimmunol. 2015;6(1):83-88.
38. Ameratunga R, Casey P, Parry S, et al. Hypogammaglobulinemia factitia-Munchausen syndrome masquerading as common variable immune deficiency. Allergy Asthma Clin Immunol. 2013;9(1):36. doi:10.1186/1710-1492-9-36.
39. Ameratunga R, Barker RW, Steele RH, et al. Profound reversible hypogammaglobulinemia caused by celiac disease in the absence of protein losing enteropathy. J Clin Immunol. 2015;35(6):589-594. doi:10.1007/s10875-015-0189-6. Epub 2015 Aug 29.
40. Quinti I, Soresina A, Guerra A, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011;31(3):315-322.
41. Rudge P, Webster AD, Revesz T, et al. Encephalomyelitis in primary hypogammaglobulinaemia. Brain. 1996;119(Pt 1):1-15.
42. Romberg N, Chamberlain N, Saadoun D, et al. CVID-associated TACI mutations affect autoreactive B cell selection and activation. J Clin Invest. 2013;123(10):4283-4293.
43. Thierry-Carstensen B, Jordan K, Uhlving HH, et al. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults. Vaccine. 2012;30(37):5464-5471.
44. Hawdon N, Nix EB, Tsang RS, et al. Immune response to Haemophilus influenzae type b vaccination in patients with chronic renal failure. Clin Vaccine Immunol. 2012;19 (6):967-969.
45. Dentinger CM, Hennessy TW, Bulkow LR, et al. Immunogenicity and reactogenicity to Haemophilus influenzae type B (Hib) conjugate vaccine among rural Alaska adults. Hum Vaccin. 2006;2(1):24-28.
46. Goldacker S, Draeger R, Warnatz K, et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol. 2007;124(3):294-303.
47. Fliegauf M, Bryant VL, Frede N, et al. Haploinsufficiency of the NFB1 Subunit p50 in Common Variable Immunodeficiency. Am J Hum Genet. 2015;97(3):389-403. doi:10.1016/j.ajhg.2015.07.008
48. Rodriguez-Cortez VC, Del Pino-Molina L, Rodriguez-Ubreva J, et al. Monozygotic twins discordant for common variable immunodeficiency reveal impaired DNA demethylation during naive-to-memory B-cell transition. Nat Commun. 2015;6:7335.
49. Ameratunga R, Woon ST. Customised molecular diagnosis of primary immune deficiency disorders in New Zealand: an efficient strategy for a small developed country. N Z Med J. 2009;122(1304):46-53.
50. Ameratunga R, Woon ST, Brewerton M, et al. Primary immune deficiency disorders in the South Pacific: the clinical utility of a customized genetic testing program in New Zealand. Ann N Y Acad Sci. 2011;1238:53-64.
51. Ameratunga R, Woon ST, Neas K, et al. The clinical utility of molecular diagnostic testing for primary immune deficiency disorders: a case based review. Allergy Asthma Clin Immunol. 2010;6(1):12.